The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease. ASMD is caused by the lack of an enzyme needed to break down the complex lipid sphingomyelin, which can accumulate in the liver, spleen, lung, and brain. Xenpozyme infusions provide enzyme...
